Why invest
Our vision is to make MOB-015, launched in Sweden and Norway under the brand name Terclara®, the leading nail fungus treatment globally, and to build a specialty pharmaceutical company with our own sales in the U.S. and sales through partners in other markets.
World-leading anti-fungal effect
- 76% of the patients became fungus-free in two phase 3 studies that included over 800 patients
- MOB-015 is a topical formulation of terbinafine. 1000 times lower concentration of terbinafine in the blood compared to oral treatment.
- Strong premium position from true competitive advantage: Targeting category leadership with USD 250-500m potential global product sales
Strong commercial partners in place
Europa
Scandinavia
Canada
Israel
Market leader in nail fungus
- Terclara® became the market leader in Sweden and Norway instantly after starting consumer marketing
- National marketing authorization approvals received in 13 European countries, whereof 7 granted OTC status.
- Builds on previous successes with the first-generation product Kerasal Nail®/Nalox®, which was sold for 1.4 billion SEK
Significant events during the latest quarter
- Moberg Pharma and Karo Healthcare enter exclusive license agreement for MOB-015/Terclara® in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key EU markets under the leading global antifungal brand Lamisil®.
- Norway: Terclara® launch nominated for “Launch of the Year” by the pharmacy chains Apotek 1 and Alliance Healthcare
- Sales data remain strong with 42% market share in Sweden and 34% in Norway for the full year 2025
Share Price